Free Trial
NASDAQ:KTTA

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Pasithea Therapeutics logo
$1.34 +0.02 (+1.52%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$1.34 +0.00 (+0.37%)
As of 03/28/2025 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Key Stats

Today's Range
$1.25
$1.39
50-Day Range
$1.03
$2.74
52-Week Range
$0.92
$9.25
Volume
50,339 shs
Average Volume
536,928 shs
Market Capitalization
$1.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Remove Ads

Pasithea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

KTTA MarketRank™: 

Pasithea Therapeutics scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pasithea Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pasithea Therapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pasithea Therapeutics is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pasithea Therapeutics has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pasithea Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.77% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently decreased by 9.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pasithea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pasithea Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.77% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently decreased by 9.20%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Pasithea Therapeutics has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Pasithea Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    Only 2 people have searched for KTTA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pasithea Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.30% of the stock of Pasithea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.92% of the stock of Pasithea Therapeutics is held by institutions.

  • Read more about Pasithea Therapeutics' insider trading history.
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTTA Stock News Headlines

Elon Musk is helping print “new gold”
MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology. It’s so valuable that some are referring to it as the “new gold”.
Pasithea announces Safety Review Committee recommendation
Big Mid-Week Move From This Small Biotech
See More Headlines

KTTA Stock Analysis - Frequently Asked Questions

Pasithea Therapeutics' stock was trading at $3.15 on January 1st, 2025. Since then, KTTA stock has decreased by 57.5% and is now trading at $1.34.
View the best growth stocks for 2025 here
.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced its quarterly earnings data on Monday, March, 24th. The company reported ($2.41) EPS for the quarter.

Pasithea Therapeutics shares reverse split on the morning of Tuesday, January 2nd 2024. The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Pasithea Therapeutics (KTTA) raised $17 million in an IPO on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA).

Company Calendar

Last Earnings
3/24/2025
Today
3/29/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KTTA
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-15,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$22.46 per share
Price / Book
0.06

Miscellaneous

Free Float
1,060,000
Market Cap
$1.70 million
Optionable
Not Optionable
Beta
0.75
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:KTTA) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners